Elicio Therapeutics (ELTX) Other financing activities (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Other financing activities came in at -$1.3 million in Q4 2025, up 94.35% YoY from -$665297.1 in Q4 2024, and down 200.0% on a QoQ basis from $1.3 million in Q3 2025.
Elicio Therapeutics (ELTX) Other financing activities (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 6 years of Other financing activities data on file, last reported at -$1.3 million in Q4 2025.
- Quarterly Other financing activities rose 94.35% year-over-year to -$1.3 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$7000.0 (up 99.88% YoY) and the FY2023 annual result came in at $127000.0, up 54.88% from the prior year.
- Other financing activities eased to -$1.3 million in Q4 2025, from $1.3 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $22.9 million in Q3 2024 to a low of -$22.9 million in Q4 2024.
- A 5-year average of $69941.2 and a median of $60000.0 in 2023 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2021 — Other financing activities soared 84400.0% — and 2024, when it tumbled 9035.82%.
- Tracing ELTX's Other financing activities over 5 years: stood at $114000.0 in 2021, then plunged by 42.98% to $65000.0 in 2022, then slipped by 7.69% to $60000.0 in 2023, then slumped by 38236.67% to -$22.9 million in 2024, then jumped by 94.35% to -$1.3 million in 2025.
- The last three Other financing activities figures came in at -$1.3 million (Q4 2025), $1.3 million (Q3 2025), and -$7000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Elicio Therapeutics | 59.08 Mn | 35.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17,000.00 |
| Jun 30, 2026 | 17,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | -1.29 Mn |
| Dec 31, 2025 | -1.29 Mn |
| Sep 30, 2025 | 1.29 Mn |
| Sep 30, 2025 | 1.29 Mn |
| Jun 30, 2025 | -7,000.00 |
| Jun 30, 2025 | -7,000.00 |
| Mar 31, 2025 | 7,000.00 |
| Mar 31, 2025 | 7,000.00 |
| Dec 31, 2024 | -22.88 Mn |
| Dec 31, 2024 | -22.88 Mn |
| Sep 30, 2024 | 22.87 Mn |
| Sep 30, 2024 | 22.87 Mn |
| Jun 30, 2024 | -5.99 Mn |
| Jun 30, 2024 | -5.99 Mn |
| Mar 31, 2024 | 6.00 Mn |
| Mar 31, 2024 | 6.00 Mn |